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Edited by Bernd HelmsAbstract Although diseases in the pathway of sphingolipid deg-
radation have been known for decades, the ﬁrst disease in the
biosynthetic pathway was only reported in 2004, when a form
of infantile-onset symptomatic epilepsy was described as a genet-
ic defect in GM3 synthase. Presumably other diseases in the
sphingolipid biosynthetic pathway will yet be discovered,
although many may remain undetected due to their putative
lethal phenotypes. In contrast, diseases are known for essentially
every step in the pathway of SL degradation, caused by the
defective activity of one or other of the lysosomal hydrolases
in this pathway. Despite the fact that some of these storage dis-
orders were ﬁrst discovered in the 19th century, the cellular and
biochemical events that cause pathology are still poorly delin-
eated. In this review, we focus on recent advances in our under-
standing of how defects in the pathways of sphingolipid
metabolism may lead to pathology. In addition, we discuss cur-
rently-available and emerging therapeutic options.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Sphingolipids (SLs) are essential membrane components of
eukaryotic cells [1], and during the past couple of decades,
SLs and their metabolites have been shown to act as intracel-
lular signaling molecules that modulate a variety of events
such as cell–cell interaction, proliferation, diﬀerentiation, cell
death, and stress responses [2,3]. Although there have been tre-
mendous advances in our understanding of the pathways of SL
synthesis and degradation, signiﬁcant gaps remain in our
knowledge concerning the precise molecular details of the sig-
naling pathways, and also in the downstream events that are
altered in genetic disorders of SL metabolism. For the latter,
diseases could presumably occur due to the defective activity
of one or other of the enzymes involved in the biosynthetic
or degradative pathways, leading to changes in the balance be-
tween speciﬁc SL signaling molecules, which is likely to have
deleterious eﬀect on cell function and survival. Diseases are*Corresponding author. Fax: +972 8 9344112.
E-mail address: tony.futerman@weizmann.ac.il (A.H. Futerman).
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[4], and the ﬁrst disease in the biosynthetic pathway was re-
cently described [5]. The relationship between SL metabolites
involved in signaling and their roles in the etiology of diseases
of SL metabolism, is largely unknown.2. The cell biology of diseases of SL metabolism
2.1. SL synthesis
The ﬁrst disease in the SL biosynthetic pathway was recently
described, characterized by an infantile-onset symptomatic
form of epilepsy [5], with aﬀected individuals suﬀering from
seizures within the ﬁrst year of life. The genetic defect is caused
by mutations in the gene encoding GM3 synthase, the enzyme
which synthesizes ganglioside GM3 from lactosylceramide
(LacCer), the ﬁrst step in the pathway of ganglioside synthesis.
Whether this disease is caused by decreased levels of GM3 or
other downstream gangliosides, or by elevation of LacCer lev-
els, is not known. Mice unable to synthesize ganglioside GM3
are viable and do not have major abnormalities [6], but mice
carrying double null mutations in both GM2 and GM3 syn-
thases develop severe neurodegenerative disease [7].
If seizures are caused by decreased levels of GM3, or another
ganglioside, this would be consistent with the important roles
that gangliosides play in neuronal development. Gangliosides
are expressed at diﬀerent levels in diﬀerent brain regions during
development [8], and it can be assumed that changes in their
levels, due to decreased or complete inhibition of biosynthesis,
would have deleterious eﬀects. In all probability, mutations
can also occur in other enzymes of SL biosynthesis, but the
essential role of SLs during development may mask their dis-
covery as they would most likely result in a lethal phenotype.
Thus, a glucosylceramide (GlcCer) synthase knockout mouse
[9] dies during embryogenesis, and a cell-speciﬁc disruption
in the GlcCer synthase gene results in major changes in neuro-
nal development [10]. Earlier work from our laboratory
showed that inhibiting SL synthesis led to signiﬁcant changes
in the rates of axonal and dendritic growth [11,12], which ap-
peared to be related to levels of GlcCer synthesis [13]. How-
ever, not all defects in the pathway of SL synthesis will
necessarily be lethal. For instance, a gene family has recently
been discovered that regulates the addition of speciﬁc fatty
acids to sphinganine, to form dihydroceramide and ceramide
[14]. Formation of ceramides containing C18-fatty acids, by
the ceramide synthase 1 (CerS1) gene (formerly known asblished by Elsevier B.V. All rights reserved.
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Fig. 1. Potential mechanisms downstream to SL accumulation in
lysosomes that may lead to altered cell function and/or cell death. For
more details, see text. The numbers in green refer to the subsections in
the description of ‘SL degradation’.
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gevity assurance gene 1 (LASS1)), was shown to be down-reg-
ulated speciﬁcally in human head and neck squamous cell
carcinomas [15], and overexpression of CerS1 increased C18-
ceramide to normal levels and inhibited cell growth, suggesting
that decreased C18-ceramide synthesis has a role in head and
neck squamous cell carcinoma cell growth, although possibly
via an indirect eﬀect. Based on the limited data currently avail-
able, we suggest that mutations in some enzymes of the SL bio-
synthetic pathway will indeed be lethal, or show very severe
phenotypes, whereas others may result in more subtle pheno-
types. Clearly much more information is required before more
speciﬁc predictions can be made, but the molecular identiﬁca-
tion of essentially all the genes in the SL biosynthetic pathway
[16] renders it likely that the next few years will see an expo-
nential increase in our knowledge of genetic defects in this
pathway.
2.2. Sphingolipid degradation
In contrast to the diseases of SL synthesis, which have only
been described recently, diseases associated with defective SL
degradation have been known for over one hundred years.
In 1881, a clinical description was reported concerning an in-
fant suﬀering from a progressive neurological deterioration,
today known as Tay-Sachs disease. In 1882, a French physi-
cian, Phillipe Gaucher, described a patient suﬀering from
splenomegaly and in 1887, skin abnormalities were described
in a patient by Fabry. At the time it was of course not known
that these diseases were caused by the defective degradation of
SLs (SLs were only discovered at around this time), but years
later it became apparent that each of these diseases was asso-
ciated with the defective activity of a particular lysosomal
hydrolase involved in SL degradation. Tay-Sachs disease is
caused by the defective activity of b-hexosaminidase, Gaucher
disease by the defective activity of acid-b-glucosidase, and
Fabry disease by defective a-galactosidase activity [4]. Cur-
rently, more than 40 lysosomal storage disorders (LSDs) are
known [4], of which at least 9 or 10 are due to defective SL deg-
radation.
LSDs are normally classiﬁed according to the type of sub-
strate that accumulates. Hence, in the sphingolipidoses or gly-
cosphingolipidoses, unmetabolized SLs or glycosphingolipids
(GSLs) accumulate due to the defective activity of an enzyme
of SL or GSL degradation. In the mucopolysaccharidoses
(MPS), glycosaminoglycans (GAGs) (mucopolysaccharides)
accumulate due to the impaired function of lysosomal enzymes
involved in their degradation, and in the oligosaccharidoses,
oligosaccharides accumulate. Interestingly, GSLs also accumu-
late in some LSDs secondarily to accumulation of the primary
storage materials (reviewed in [17]). For instance, brain storage
of gangliosides GM2 and GM3 has been documented in Nie-
mann-Pick type A disease, in which the primary storage mate-
rial is sphingomyelin (SM), in Niemann-Pick type C disease,
where the primary storage material is cholesterol, and also in
MPS types I and III, where the primary storage materials
are dermatan sulphate and heparan sulphate.
Despite the diﬀerent types of substrates that accumulate in
diﬀerent LSDs, they share many common clinical manifesta-
tions, e.g. central nervous system dysfunction, organomegaly
and bone abnormalities. However, the clinical course and the
severity of individual diseases diﬀer widely between each other,
although a common principle, namely that the clinical severityin general correlates with levels of residual enzyme activity
[18], appears to hold true in most diseases. When little or no
residual enzymatic activity is detected, severe phenotypes nor-
mally ensue, characterized by a progressive neurodegenerative
course leading to death in early infancy. When residual enzyme
activity is somewhat higher, disease symptoms are often
milder, but the clinical features can vary widely. In type 1 Gau-
cher disease, Niemann-Pick type B, and Fabry disease, pathol-
ogy occurs mainly in visceral organs, with little or no
neurological involvement, but in other diseases neuropathol-
ogy may be the only manifestation of the disease, with little
or no visceral abnormalities, as observed in the sialidosis and
in Tay-Sachs disease [4,19]. Some LSDs are more prevalent
among certain ethnic groups, such as the high incidence of
Gaucher disease among Ashkenazi Jews, occurring in 1 of
855 live births, compared to only 1 in 57000 in the general
population. Similarly the prevalence of Tay-Sachs disease
among Ashkenazi Jews is 1 in 3900 live births [20] compared
to 1 in 200000 in the general population [21]. Despite the
low frequency of each individual disease, they nevertheless
constitute a signiﬁcant group of disorders with a collective fre-
quency of 1 in 5000 live births, and are the most common
cause of pediatric neurodegenerative diseases [21,22].
We now discuss what is known about the cellular pathology
of these diseases, that is to say, how accumulation of a speciﬁc
SL results in alterations in cell and tissue function and hence
disease. However, it should be stated at the outset that there
is no single unifying theory to explain the link between SL
or GSL accumulation and pathology. Perhaps this is not unex-
pected, since SLs and GSLs play multiple roles in cell physiol-
ogy, and indeed it might be a rather naı¨ve view to expect a
’unifying theory’. Nevertheless, some pathways that are altered
in some of the diseases have been identiﬁed over the past few
years, and we will highlight those which recent progress sug-
gests may be centrally involved in the pathology of SL storage
diseases, as summarized in Fig. 1.
2.2.1. Lipid traﬃcking. The possibility that defective intra-
cellular lipid traﬃcking may be responsible for some of the
pathology in the sphingolipidoses is based on the interesting
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ative of LacCer is targeted to the Golgi apparatus in normal
cells, but to endosomes and lysosomes in cells from sphingol-
ipidoses patients [23,24], implying a common defect in lipid
sorting and transport in the diﬀerent sphingolipidoses
[25,26]. This process is linked to the accumulation of unesteri-
ﬁed cholesterol [27] and to the activity of the small GTPases,
Rab7 and Rab9 [28]. The fact that cholesterol and SL levels
are inter-related in LSDs is hardly surprising because both
are important components of microdomains/rafts at the cell
surface [29]; indeed, changes in cholesterol levels are observed
in LSDs that are caused by defective SL hydrolysis, such as
Niemann-Pick A and B. A recent study has shown that SLs
are diﬀerentially required for distinct mechanisms of clathrin-
independent endocytosis [30], and can even regulate clathrin-
independent mechanisms of endocytosis. This being the case,
it appears axiomatic that alteration of levels of one or other
SL in sphingolipidoses cells and tissues is likely to aﬀect multi-
ple vesicular pathways that depend on endocytosis. Clearly,
this is an area that will be intensively studied in the years
ahead.
2.2.2. Inﬂammation. Inﬂammation, a local response to cel-
lular insult, has been demonstrated in a number of sphingo-
lipidoses. Progressive central nervous system (CNS)
inﬂammation, which correlates with the onset of clinical signs,
has been detected in Tay-Sachs, Sandhoﬀ and GM1 ganglios-
idoses mouse models [31]. In Tay-Sachs and Sandhoﬀ disease
models, over-expression of genes associated with activated
macrophages, microglia and astrocytes, was found by gene
array analysis [32,33]. In an immunohistochemical study on
microglia in a mouse model of Niemann-Pick type C disease,
in which gangliosides GM2 and GM3 accumulate as secondary
storage materials, inﬂammation was shown to occur post-na-
tally [34], suggesting that microglial activation precedes and
might be causally related to neuronal degeneration.
In type I Gaucher disease, GlcCer, the primary storage
material, accumulates mainly in cells of mononuclear phago-
cyte origin. Alterations in levels of a number of macrophage-
derived molecules have been observed (reviewed in [35]). For
instance, levels of interleukin-1a (IL-1a), interleukin-1 receptor
antagonist, interleukin-6 (IL-6), tumor necrosis factor-a
(TNFa), and soluble interleukin-2 receptor (sIL-2R) are ele-
vated in the serum of Gaucher patients [36], as are CD14
and M-CSF [37]. Changes in levels of other macrophage-
derived markers have also been reported in the plasma of
Gaucher disease patients. However, on macrophages them-
selves, expression of pro-inﬂammatory mediators is not always
apparent [38], although markers characteristic of alternatively
activated macrophages are found.
Even though the levels of many pro-inﬂammatory mediators
are elevated in the plasma of Gaucher disease patients, the ini-
tial trigger causing the response is unknown, i.e. the relation-
ship between accumulation of lysosomal GlcCer and the
production of pro-inﬂammatory mediators has not been deter-
mined. One possibility is that changes in intracellular calcium
levels in macrophages may cause changes in the expression of
inducible nitric oxide synthase [39], which would imply a role
for calcium in the control of the inﬂammatory response. The
role of defective calcium homeostasis in the sphingolipidoses,
at least in neuronal tissues, is discussed next.
2.2.3. Calcium homeostasis. Over the past 5–6 years, our
laboratory has shown that defective intracellular calciumhomeostasis plays a central role in the neuropathophysiology
of a number of SL storage diseases. In retrospect, this is per-
haps not surprising, since calcium is important in regulating
a great variety of neuronal processes. Mechanisms responsible
for regulating cytosolic calcium levels involve external calcium-
inﬂux via voltage- and ligand-gated channels in the plasma
membrane, along with release of calcium from intracellular
stores [40,41]. In excitable cells, calcium induces immediate
responses such as muscle contraction or neurotransmitter re-
lease, and calcium can induce long-term responses via activa-
tion of signal transduction cascades in all cell types. Altered
calcium-homeostasis was demonstrated in brain pathophysiol-
ogy in several neurological diseases, such as epilepsy [42],
stroke [43] and Alzheimer’s disease [44], and we have demon-
strated altered calcium homeostasis in three models of SL stor-
age diseases, namely Gaucher disease [45], Sandhoﬀ disease, in
which GM2 is the primary accumulating material, and Nie-
mann-Pick type A disease, in which SM is the primary accu-
mulating material.
The mechanism leading to altered calcium homeostasis in
each of these three diseases is quite distinct. Neurons that accu-
mulate GlcCer are more sensitive to calcium-induced neuro-
toxicity via a mechanism that involves calcium release via
the ryanodine receptor, a calcium channel located in the endo-
plasmic reticulum (ER). In brain microsomes derived from a
mouse model of Sandhoﬀ disease (the Hexb/ mouse [46]),
a signiﬁcant reduction in the rate of calcium uptake via the
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) was ob-
served [47]. Reduced rates of calcium uptake via SERCA were
also demonstrated in the cerebellum, but not in the cerebral
cortex, of microsomes derived from acid sphingomyelinase
(A-SMase)-deﬁcient mice (ASM/), a model of Niemann-
Pick disease type A. However, the mechanism responsible for
the impaired calcium homeostasis is diﬀerent from the Sand-
hoﬀ disease mouse model inasmuch as levels of SERCA
expression are signiﬁcantly reduced in the ASM/ cerebel-
lum by 6–7 months of age, immediately prior to death of the
mice, as are levels of the inositol 1,4,5-triphosphate receptor
(IP3R), the major calcium release channel in the cerebellum
[48]. Altered calcium homeostasis was also demonstrated in a
mouse model of another GSL storage disease, namely the
GM1 gangliosidosis, in which GM1 is the primary accumulat-
ing lipid [49].
A number of biochemical pathways are known to be acti-
vated upon either depletion of ER calcium-stores or upon ele-
vation of cytosolic calcium levels. Activation of one or other of
these pathways may be a downstream response to SL or GSL
accumulation. Mobilization of ER calcium stores, as well as
other ER stress-inducing stimuli, initiates activation of a cyto-
plasmic apoptotic pathway mediated by ER-localized caspase
12 [50], and upon depletion of ER calcium stores, cells can en-
ter a form of ER stress, the ’unfolded protein response’ (UPR)
[51], which causes suppression of global protein synthesis, acti-
vation of stress-induced gene expression, and induction of
apoptosis [52,53].
2.2.4. ER stress, UPR activation and apoptosis. A growing
body of evidence is accumulating that implies a role for ER
stress-mediated apoptosis in chronic neurodegenerative dis-
eases [54–56]. This mechanism of neuronal cell death, i.e. acti-
vation of the UPR cascade by depletion of ER calcium stores,
has been demonstrated in the GM1 gangliosidosis [49], in
which a link between GM1 accumulation, altered calcium con-
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degeneration, was demonstrated in neurons from the
b-Gal/ mouse, a model of the GM1 gangliosidosis. In post-
mortem brain tissues from patients of another neurodegenera-
tive LSD, infantile neuronal ceroid lipofuscinosis, ER stress-
induced activation of the UPR was also detected [57]. Since
apoptotic cell death has been reported in a number of SL
and GSL storage diseases (reviewed in [19]), the exciting possi-
bility exists that ER stress, leading to apoptosis, may play a
vital role in the pathology of many of these diseases, not only
in the neuronal forms, but also in tissues such as macrophages,
in which ER stress has also been implied as a trigger for apop-
tosis [51].
2.2.5. Phospholipid metabolism and altered rates of
growth. The mammalian UPR has been directly linked to
phospholipid synthesis. Thus, biosynthesis of phosphatidyl-
choline (PC), the primary phospholipid of the ER membrane,
can be modulated upon induction of the UPR [58]. Since
phospholipid metabolism is crucial in cell signaling, and regu-
lates rates of cell growth, proliferation and apoptosis [59,60],
altering rates of phospholipid synthesis is likely to have pro-
found eﬀects on cellular morphology, including the rate of neu-
ronal growth [61]. That this may also be connected to calcium
homeostasis is supported by the observation that a narrow
range of cytosolic calcium levels is optimal for axon outgrowth
and branching. For instance, loss of IP3R function in chick
dorsal root ganglion growth cones inhibits neurite extension
[62], and localized and transient elevation in free intracellular
calcium triggers de-diﬀerentiation of the axonal segment into
a growth cone and subsequent formation of ectopic neurites
[63], similar to that observed in some sphingolipidoses [64].
Exposure of cultured neurons to thapsigargin at a concentra-
tion that inhibits depolarization-induced calcium signals,
results in a reduction in neurite initiation, while eliciting
RyaR-mediated calcium release by caﬀeine increases neurite
elongation [65].
We have shown a correlation between SL and GSL accumu-
lation and the stimulation of neuronal growth [66]. Inhibition
of GSL synthesis reduced rates of axonal [11,66] and dendritic
[12] growth in cultured neurons, and axonal growth was
increased in hippocampal neurons cultured from a Gaucher
mouse model [45] (the Gba/ mouse [67]). In contrast, axo-
nal growth was decreased in hippocampal neurons cultured
from Hexb/ mice [68], correlating with the reduced
phospholipid synthesis observed in brain tissues of these mice
[69]. Likewise, a correlation has been shown between macro-
phage size and the rate of PC synthesis [70]. Together, these re-
sults suggest that the rate of neuronal growth may be directly
correlated with some of the events discussed above, such as
altered calcium homeostasis, the UPR, and rates of phospho-
lipid synthesis. Since these events occur in the ER, we have
suggested that at least some of the pathophysiology of SL
and GSL storage diseases depends on events that occur outside
of the lysosome (reviewed in [4,71]). If this is correct, then ther-
apeutic approaches will need to take extra-lysosomal storage
material into account.3. Therapeutic options
Since diseases in the SL biosynthetic pathway have only re-
cently been discovered, no serious thought has yet been givento how these diseases might be treated. If the pathology of
these diseases is caused by a reduction in a downstream lipid,
such as GM3, as possibly in the case of the infantile-onset
symptomatic form of epilepsy discussed above [5], then replen-
ishing GM3 levels might potential reverse symptoms. How-
ever, since SLs and GSLs are notoriously insoluble in
aqueous solutions, this simple-minded approach is unlikely
to work. Similar to the sphingolipidoses, the most eﬀective
treatment would be gene therapy, but to date, gene therapy
has not been used successfully to treat any disease. Fortu-
nately, in the case of the sphingolipidoses, a number of thera-
peutic options are available, which are discussed brieﬂy below,
including enzyme replacement therapy (ERT), substrate reduc-
tion therapy (SRT), enzyme enhancement therapy (EET)
(otherwise known as chaperone therapy) (see Fig. 2), in addi-
tion to various other symptomatic treatments which address
disease symptoms rather than the underlying biochemical
cause. Examples of the latter are biphosphonate treatment of
type 1 Gaucher disease patients so as to increase bone density
and to prevent irreversible bone complications [35], or the use
of chronic haemodialysis and renal transplantation for renal
insuﬃency in Fabry disease patients.3.1. Enzyme replacement therapy
ERT is the most successful available treatment for any SL
storage disease, and >3000 type 1 Gaucher disease patients
are currently being treated by this approach. ERT acts by sup-
plementing defective enzyme with active enzyme, and has
proved to be safe and eﬀective over a period of >14 years.
Reduction in organ volumes, improvement in hematological
parameters and amelioration of bone pains have dramatically
improved quality of life for many patients [35,72]. Recombi-
nant acid b-glucosidase (Cerezyme) is targeted to macro-
phages by remodeling its oligosaccharide chains so as to
expose mannose residues, permitting uptake via macrophage
mannose receptors. However, despite the notable success of
ERT in treating patients with type 1 Gaucher disease, few at-
tempts have been made to improve the eﬃcacy of ERT by pro-
duction of second generation enzymes. Thus, engineering a
more stable enzyme, or an enzyme with a higher catalytic
activity, could reduce the number of infusions and potentially
also reduce cost, and the recent availability of the 3D-structure
of acid b-glucosidase should help in this regard [73]. Moreover,
Cerezyme generally has a poor eﬀect on bones and lungs in
patients with pre-existing lesions, does not cross the blood–
brain barrier, and of no less importance is expensive and there-
fore unavailable to patients in poor countries.
The use of ERT for a number of other LSDs [74], and the
appearance on the market of alternative forms of recombinant
acid b-glucosidase, should stimulate research in this area.
Moreover, a recent study has shown that a high dose of en-
zyme can help overcome the blood–brain barrier in a murine
model of MPS VII [75], suggesting that some strategies using
ERT might be applicable for LSDs in which the brain is the
main aﬀected organ; however, it seems more likely that the
newer therapeutic approaches described below will be of more
relevance for LSDs which aﬀect the brain.3.2. Substrate reduction therapy (SRT)
This therapeutic approach is based on preventing the accu-
mulation of the undegraded substrates by partial inhibition
Golgi
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Lysosome Enzyme
replacement
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Ceramide
Chaperone therapy (3)
ER
Gene therapy (4)
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Fig. 2. Therapeutic options in SL storage diseases. Examples are shown for Gaucher disease, in which GlcCer accumulates. For more details, see
text. The numbers refer to the subsections in Section 3.
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type 1 Gaucher disease patients, by partial inhibition of GSL
synthesis by N-butyldeoxynojirimycin (Zavesca) [76–78], and
could potentially be used for other GSL storage diseases, such
as Tay-Sachs disease [79]. Zavesca has been approved in Eur-
ope and the USA for Gaucher patients for whom ERT is
unsuitable. Presumably, these molecules, in contrast to the
enzymes used in ERT, could pass through the blood–brain
barrier. However, since GSLs play crucial roles in neuronal
development and function [80], it is unclear whether deleteri-
ous side-eﬀects might be observed in patients after extended
use [72]. Studies are currently underway to develop second
generation molecules for SRT, with a view to perhaps using
these molecules in combination therapies with other drugs
and treatments.
3.3. Enzyme enhancement therapy (EET) (or chaperone
therapy)
This is the most recent addition to the spectrum of potential
therapies that have become available to LSD patients over the
past few years. The treatment is based on the concept that
some mutations in LSDs cause the misfolding of lysosomal en-
zymes after their synthesis in the ER. When this occurs, most
of the newly-synthesized enzyme is degraded in the ER rather
than being transported to the lysosome. If the enzyme could be
stabilized during its synthesis by the use of small chemical
chaperones, then this would provide another therapeutic op-
tion [81–83]. This strategy has been shown to be successful in
various disease models [83,84] and is currently being evaluated
in clinical trials.3.4. Gene therapy
Gene therapy is the ultimate therapeutic option not only for
LSDs, but for many other monogenic diseases. This article is
not the place to review all of the various issues associated with
gene therapy, and readers are referred to some recent excellent
reviews [83,85,86] dealing with this issue. However, it should
be stressed that several issues must be resolved before gene
therapy could be an eﬀective tool in the clinic, and although
proof of concept in animal models is an essential ﬁrst step,
the real challenge will be overcoming safety, eﬃcacy and ethi-
cal issues in human patients.4. Concluding remarks
In this review, we have attempted to give a brief overview of
recent advances in delineating the mechanisms responsible for
disease pathology in metabolic diseases of SL and GSL metab-
olism, as well as discuss currently-available therapeutic op-
tions. The past few years have seen a reinvestment of
research energy in both of these areas, and we anticipate that
major advances are on the horizon that will propel this ﬁeld
back into the mainstream of lipid and SL biology, and will also
provide real hope for patients suﬀering from these debilitating
diseases.
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